Buy Rating for Structure Therapeutics, Inc.: Potential Disruption in Obesity Treatment with Amylin Agonists
Wall Street analyst Patrick Dolezal from LifeSci Capital maintained a Buy rating on Structure Therapeutics, Inc. with a $72.00 price target, citing the potential of their small molecule amylin agonists in obesity treatment. The company's lead candidate, ACCG-2671, is set for trials by 2025, with promising efficacy in weight loss. BMO Capital also reiterated a Buy rating with a $100.00 target, highlighting the company's potential to disrupt the obesity treatment market.
Structure Therapeutics, Inc. Sponsored ADR, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Dolezal from LifeSci Capital maintained a Buy rating on the stock and has a $72.00 price target.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Patrick Dolezal has given his Buy rating due to a combination of factors that highlight the potential of Structure Therapeutics, Inc.’s small molecule amylin agonists. The company’s lead candidate, ACCG-2671, is poised to enter first-in-human trials by the end of 2025, and the amylin class itself is gaining traction for its promising efficacy and gastrointestinal tolerability in obesity treatment.
The amylin mechanism offers a more central nervous system-specific approach to weight loss compared to glucagon-like peptide-1 (GLP-1), potentially providing a competitive advantage in the obesity market. Structure’s assets could disrupt the current therapeutic landscape, and the anticipated clinical data in 2026 may serve as a significant catalyst for the company’s valuation.
In another report released on November 20, BMO Capital also reiterated a Buy rating on the stock with a $100.00 price target.
